Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Oct 15 - Oct 20
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
High stress levels (i.e
8-12 hours IM) Preferred by 64% of patients who've tried both Intramuscular (into deltoid or vastus lateralis, using a 22-25 gauge, 1-inch needle): 41% report injection-site soreness Faster absorption More difficult self-administration for some sites (deltoid requires non-dominant arm injection) Preferred by 36% of patients who've tried both The efficacy difference is minimal
The Bottom Line AOD 9604 is an intriguing peptide therapy that may help support fat metabolism and healthy aging, particularly for adults over 50 dealing with stubborn weight gain and metabolic changes
That means at each shot should be at least 5,000mcg of methylcobalamin NOT cyanocobalamin
